John Mascarenhas, MD, presents the case of a 76-year-old woman with myelofibrosis and provides his initial impressions.
A 76-Year-Old Woman with Myelofibrosis
Dr John Mascarenhas explains the differences between myelofibrosis phenotypes and why it affects treatment regimen choices.
An expert describes the factors he considers when choosing a treatment for a patient with myelofibrosis, and how he judges treatment response.
Dr John Mascarenhas reviews the mechanism of action of pacritinib, a selective JAK2 inhibitor.
John Mascarenhas, MD, describes his personal experience with using pacritinib to treat patients with myelofibrosis and reviews the study design and outcomes for both the PERSIST-1 and PERSIST-2 trials.
Dr John Mascarenhas looks to the future of myelofibrosis treatment and shares some ongoing clinical trials and potential treatments that excite him.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
